Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

It's currently under consideration as a first-line treatment for advanced or metastatic malignant pleural mesothelioma, among ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

The complexity of the legal landscape often presents an additional burden to the already overwhelming diagnosis of mesothelioma. In California, myriad legal issues arise for these patients, including ...

Well-differentiated papillary mesothelioma of the pleura is a rare variant in the spectrum of pleural neoplasmas. This disease has initially been described in the peritoneum of young women without ...

Merck & Co's Keytruda has met two survival goals in a key first-line lung cancer trial – another victory for the company in the battle for supremacy in the immunotherapy market. Combining ...